ZURA
Zura Bio Ltd
NASDAQ · Healthcare · Biotechnology · US
$3.81
−1.80%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -29.3%
- EBIT
- -28.2%
- EPS
- -48.7%
- Free cash flow
- -77.7%
- Operating cash flow
- -78.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +32.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -30.9%
- EBIT
- -36.3%
- Net income
- -31.0%
- EPS
- -76.7%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026